Chronic joint inflammation is a hallmark of the systemic inflammatory illness known as rheumatoid arthritis (RA), which ultimately causes severe disability and early death. Around 1% of people worldwide are affected by it, and women are 2-3 times more likely to be affected than males. Preclinical RA, genetic influences and environmental influences all have a role in the etiology of the illness. Since there is no recognized treatment for RA, achieving the lowest disease activity and, if possible, recovery remains the key goals of care. The literature on the various RA therapy options, their mechanisms of action, side effects and innovative drug delivery systems that are currently being used for medication administration are highlighted in this review, with non-steroidal anti-inflammatory drug delivery systems receiving the most attention. The most popular medications from each class are reviewed, including corticosteroids, non-steroidal anti-inflammatory medicines (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Traditional medication therapy has various drawbacks, including inadequate bioavailability, first pass metabolism, gastrointestinal enzyme degradation, limited solubility and permeability, food interactions and toxicity. Innovative drug delivery technologies such as microspheres, nanoparticles, dendrimers, liposomes and others, hold great promise since they have been able to overcome the drawbacks of traditional drug delivery systems. The current review compares and contrasts numerous unique drug delivery methods that have been investigated for using anti-rheumatic medications, as well as the benefits of using these novel methods over traditional drug delivery methods.
Cite this article:
Bhashpitha Naredla, Usharani Sagarla, Prasanthi. D. Updates on Novel Treatments for Rheumatoid Arthritis. Research Journal of Science and Technology. 2023; 15(4):225-2. doi: 10.52711/2349-2988.2023.00039
Bhashpitha Naredla, Usharani Sagarla, Prasanthi. D. Updates on Novel Treatments for Rheumatoid Arthritis. Research Journal of Science and Technology. 2023; 15(4):225-2. doi: 10.52711/2349-2988.2023.00039 Available on: https://rjstonline.com/AbstractView.aspx?PID=2023-15-4-11
1. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 1996; 39(11): 1781-90. doi: 10.1002/art.1780391103.
2. Spandana K, Varun Teja Chary, Shivani. M, Rheumatoid arthritis, Research Journal of Pharmaceutical Dosage Forms and Technology, 2019; Vol. 11(02), doi: 10.5958/0975-4377.2019.00021.1.
3. D Kilimozhi, V Parthasarathy and N Amuthavalli, Effect of Delonix elata on Adjuvant Induced Arthritis in Rats - A Radiographic Densitometric Analysis, Research J. Pharmacology and Pharmacodynamics 2009; 1(1): 25-30.
4. Siddhesh Gosavi, Pranali Joshi, Vidur Bhogate, Sairaj Gawade, Pooja Sangelkar, Shraddha Kanekar, Comparative Study on Treatment of Rheumatoid Arthritis, 2021; Vol. 11(01), doi: 10.5958/2231-5713.2021.00002.7.
5. Park J., and Ernst, E. Ayurvedic medicine for rheumatoid arthritis: A systematic review. Seminars in Arthritis and Rheumatism,2005;34(5), 705–713. doi:10.1016/j.semarthrit.2004.11.005.
6. Trapti Rastogi, Deepali S Ghorpade, UA Deokate and SS Khadabadi, Studies on Antimicrobial Activity of Boswellia serrata, Moringa oleifera and Vitex negundo: A comparison, Research Journal of Pharmacognosy and Phytochemistry.2009; 1(1), 75-77.
7. Sankalp Goswami, Prachi Sharma and Yogesh Shivhare, Phytopharmaceuticals as Cosmetic Agents: A Review, Research J. Topical and Cosmetic, 2011;Sci. 2(1): Jan. – June,page 11-13.
8. Dunn, J. M., and Wilkinson, J. M. Naturopathic management of rheumatoid arthritis. Modern Rheumatology,2005;15(2), 87–90. doi:10.3109/pl00021706.
9. Zhang, P., Li, J., Han, Y., Wei Yu, X., and Qin, L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheumatology International, 2010;30(6), 713–718. doi:10.1007/s00296-010-1370-0
10. Casimiro, L., Barnsley, L., Brosseau, L., Milne, S., Robinson, V., Tugwell, P., and Wells, G. Acupuncture and electroacupuncture for the treatment of RA. The Cochrane Database of Systematic Reviews. 2002; doi:10.1002/14651858.cd003788.
11. Kanchan R Pagar, Sarika V Khandbahale, A Review on Novel Drug Delivery System: A Recent Trend, 2019; Vol. 09(02), DOI: 10.5958/2231-5713.2019.00023.0.
12. Sarika V. Khandbahale1, Prof.Dr.R.B.Saudagar, Nanoparticle- A Review, 2017;Vol. 7(3), doi: 10.5958/2231-5659.2017.00026.
13. Bosch, X.Dendrimers To Treat Rheumatoid Arthritis. ACS Nano,2011; 5(9), 6779–6785. doi:10.1021/nn203190x.
14. Shashikant Chandrakar and Swarnalata Saraf, Niosome - A Versatile Tool in Transdermal Drug Delivery, Pharmaceutical Dosage Forms and Technology. 2009; vol 1(1), 01-04.
15. Sharma, V., Nayak, S. K., Paul, S. R., Choudhary, B., Ray, S. S., and Pal, K, Emulgels. Polymeric Gels,2018; 251–264. doi:10.1016/b978-0-08-102179-8.00009-0.
16. Chen, H., Chang, X., Weng, T., Zhao, X., Gao, Z., Yang, Y., … Yang, X. A study of microemulsion systems for transdermal delivery of triptolide. Journal of Controlled Release,2004, 98(3), 427–436. doi:10.1016/j.jconrel.2004.06.001.
17. Chunhong Li, Hanmei Li, Qin Wang, Meiling Zhou, Man Li, Tao Gong, Zhirong Zhang, Xun Sun pH-sensitive polymeric micelles for targeted delivery to inflamed joints,, 2017;vol 246,133–141, https://doi.org/10.1016/j.jconrel.2016.12.027.
18. Raghavendra Babu N, Padmavathi.Y, Priyanka.S, Ravi Kumar.P, Development of Sensitive Spectrophotometric Method for Analysis of Darifenacin Hydrobromide Liposomes in Rat Plasma, 2017; Vol. 7(1), doi: 10.5958/2231-5675.2017.00008.4.
19. Tahani Saeedi, Hadil Faris Alotaibi, Polina Prokopovich, Polymer colloids as drug delivery systems for the treatment of arthritis,2020; vol 285, https://doi.org/10.1016/j.cis.2020.102273.
20. Shweta Jain, Shalini Tripathi, Pushpendra Kumar Tripathi, Invasomes: Potential vesicular systems for transdermal delivery of drug molecules, 2021; vol 61, https://doi.org/10.1016/j.jddst.2020.102166.
21. Chando Anita, Momin Munira, Quadros Mural, Lalka Shaily, Topical nanocarriers for management of Rheumatoid Arthritis: A review, 2021; vol 141, https://doi.org/10.1016/j.biopha.2021.111880.
22. Lakshmi,V Sree, Manohar, R Deepa, Mathan, S, Dharan, Shaiju S, Ufasomes: A Potential Vesicular Carrier System,2020; Vol. 12(10), 1332-1335.
23. Ruckmani K., Sivakumar M., and Ganeshkumar, P. A.Methotrexate Loaded Solid Lipid Nanoparticles (SLN) for Effective Treatment of Carcinoma. Journal of Nanoscience and Nanotechnology,2006; 6(9), 2991–2995. doi:10.1166/jnn.2006.457.
24. Margarita Shumilov, Ronny Bercovich, Shaher Duchi, Denzie Ainbinder, and Elka Touitou, ibuprofen transdermal ethosomal gel: characterization and efficiency in animal model, 2010; vol.6, 569-576.
25. Norazlinaliza salim, Maria Jose DGarcia-Celma, Elvaira Escribano, Jordi Nolla, Mertixell Llinas, Mahiran Basri, Conxita Solans, Tharwat F Tadros, formulation of nanoemulsion containing inuprofen by PIC method for topical delivery 2018; S172-S179.
26. Eskandar Moghimipour, Anayatollah Salami and Mahsa Monjezi, Formulation and Evaluation of Liposomes for Transdermal Delivery of Celecoxib 2015 Feb; 10(1): e17653. doi: 10.17795/jjnpp-17653.
27. Saikat Ghosh,Biswajit Mukherjee, Shreyasi Chaudhuri, Tanushree Roy, Alankar Mukherjee, and Soma Sengupta, Methotrexate Aspasomes Against Rheumatoid Arthritis: Optimized Hydrogel Loaded Liposomal Formulation with In Vivo Evaluation in Wistar Rats 2017; DOI: 10.1208/s12249-017-0939-2.
28. Somayeh Taymori, Valiollah Hajishemi, majid Tabbakhian and Massoud Torkashvand. Preparation and Evaluation of Imatinib Loaded Transfersomal gel for the Treatment of Rheumatoid Arthritis 2021; 20(4): 33–46. doi: 10.22037/ijpr.2021.115481.15394.
29. Sharma, A., and Arora, S. Formulation and In Vitro Evaluation of Ufasomes for Dermal Administration of Methotrexate. ISRN Pharmaceutics, 2012;1–8. doi:10.5402/2012/873653.